WO2024224304 - ORAL PHARMACEUTICAL COMPOSITIONS
National phase entry is expected:
Publication Number
WO/2024/224304
Publication Date
31.10.2024
International Application No.
PCT/IB2024/053990
International Filing Date
24.04.2024
Title **
[English]
ORAL PHARMACEUTICAL COMPOSITIONS
[French]
COMPOSITIONS PHARMACEUTIQUES ORALES
Applicants **
ASSEMBLY BIOSCIENCES, INC.
Inventors
ZONG, Zhixin
WHITE, Nicole
WU, Yi
Priority Data
63/498,398
26.04.2023
US
63/522,996
23.06.2023
US
63/553,453
14.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3095 | |
| EPO | Filing, Examination, Granting | 15120 | |
| Japan | Filing, Examination, Granting | 2419 | |
| South Korea | Filing, Examination, Granting | 2610 | |
| USA | Filing, Examination, Granting | 7590 |
Total:
30,834
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to methods and compositions for treating and/or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection. In particular, provided are oral high bioavailability and long-acting pharmaceutical compositions comprising Compound 1; methods for their manufacture; and the use of said pharmaceutical compositions as a medicament and for the treatment of diseases or disorders caused by, or associated with, herpes virus.[French]
La présente invention concerne des procédés et des compositions pour traiter et/ou inhiber le développement ou la progression de maladies ou de troubles provoqués par, ou associés à, une infection par le virus de l'herpès. En particulier, l'invention concerne des compositions pharmaceutiques orales à biodisponibilité élevée et à action prolongée comprenant le composé 1 ; des procédés pour leur fabrication ; et l'utilisation desdites compositions pharmaceutiques en tant que médicament et pour le traitement de maladies ou de troubles provoqués par le virus de l'herpès ou associés à celui-ci.